NASDAQ:THOR - Thoratec Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Thoratec (NASDAQ:THOR)

Thoratec logoThoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company's products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company's product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNASDAQ:THOR
CUSIP88517530
Phone+1-925-8478600

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins10.29%
Return on Equity8.02%
Return on Assets6.71%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Thoratec (NASDAQ:THOR) Frequently Asked Questions

What is Thoratec's stock symbol?

Thoratec trades on the NASDAQ under the ticker symbol "THOR."

How were Thoratec's earnings last quarter?

Thoratec Co. (NASDAQ:THOR) announced its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.09. The medical instruments supplier had revenue of $128.70 million for the quarter, compared to analyst estimates of $115.48 million. Thoratec had a net margin of 10.29% and a return on equity of 8.02%. The company's revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.43 EPS. View Thoratec's Earnings History.

Has Thoratec been receiving favorable news coverage?

News stories about THOR stock have been trending somewhat positive on Monday, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Thoratec earned a media sentiment score of 0.13 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 45.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Thoratec?

Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Thoratec?

Thoratec's mailing address is 6035 Stoneridge Dr, PLEASANTON, CA 94588, United States. The medical instruments supplier can be reached via phone at +1-925-8478600.


MarketBeat Community Rating for Thoratec (THOR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  580
MarketBeat's community ratings are surveys of what our community members think about Thoratec and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.